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An outline of the development of a ‘‘brave new partnership’’ in clinical trials is provided in
this specific personal account. This paper was one of several delivered in November 2007
by colleagues deemed to have contributed to the distinguished career of Professor Michael
Baum, at a Festschrift convened to honour him. This account describes this strange, new
doctor–patient relationship in the research process that we developed, both in our dia-
logues and in the work of the Consumers’ Advisory Group for Clinical Trials (CAG-CT)
that we jointly founded. This work formed but one facet of his outstanding contribution
to society and academe, in the fields of medicine, ethics and science.
ª 2008 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.‘‘Thus not only morality but also scientific self-interest combine
to urge the ‘brave new partnership’ between clinical trialists
and patients advocated by Mrs. Thornton. Like all partnerships
it requires understanding by each partner of the interests and
objectives of the other when those interests and objectives are
perceived to conflict.’’
Raanon Gillon.
‘‘Recruitment for clinical trials: the need for public-professional
co-operation’’.11. Introduction
I’m delighted to have this wonderful opportunity to partici-
pate in Michael Baum’s Festschrift. It is an honour to be num-
bered amongst those colleagues deemed to have contributed
to his distinguished career. He acknowledged this contribu-
tion when giving his acceptance speech in St. Gallen in March
this year when he received the prestigious St. Gallen Lifetime
Achievement Award for Advancement in Breast Cancer ResearchColchester CO5 7EA, UK.
hed by Elsevier Ltd on bewhich he dedicated ‘‘to the amazing people I have worked
with over the years and to the many thousands of patients
and their families who have in some way benefited from the
great advances in research and treatment’’.2 It was a very
moving occasion for everyone present, but particularly for
me when he mentioned my name.
I hope now to be able to convey to you some of his partic-
ular qualities and attributes that I discovered and appreciated
as we explored and developed this ‘‘brave new partnership’’,
this strange, new doctor–patient relationship in the research
process which formed but one facet of his outstanding contri-
bution to society and academe, in the fields of medicine,
ethics and science.2. The nature of the relationship
‘‘Scientists and patient advocates have always enjoyed a delicate
relationship’’.3Tel.: þ44 (0)1206 728178; fax: þ44 (0)1206 728911.
half of Surgical Associates Ltd.
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ductive ‘‘brave new partnership’’ between two apparently
unmatched individuals? Two TV programmes, shown one
after the other in August this year, depicting two extraordi-
nary relationships, provide modern and Victorian parables.
The first was a visually stunning documentary showing TV
presenter and novice rock-climber, Julia Bradbury, tackling
one of Britain’s most dangerous ascents of the Old Man of
Stoer, a 60 m sandstone sea stack on the Scottish Sutherland
coast, in the company of professional rock-climber, Tim
Emmett.4 The second was the acclaimed film Mrs. Brown, in
which the story is told of the summoning by Queen Victoria’s
Secretary, Sir Henry Ponsonby, of servant John Brown from
Scotland, a favourite riding companion of Prince Albert, to
help lift the Queen’s prolonged depression after Prince
Albert’s death.5
The rock-climbing partnership vividly demonstrated
a relationship in which all the energies and efforts of
both people were concentrated solely on the identified
common goal to which they had committed themselves –
no turning back was possible. No time was wasted on un-
related, un-essential facets of each other’s lives that had
no bearing on the task in hand. It was a working relation-
ship that demanded complete and full concentration solely
on the necessary elements of the challenging undertaking.
But, as one could see, there was a strong rapport and in-
tensity of purpose, evidently based on trust in each other,
and confidence in the skills and personal characteristics of
each person for the other. A paring down to vital practical
and personal essentials, with economy of expression and
measured pace: novice and expert roped together to reach
the summit!
The John Brown/Queen Victoria relationship flew in the
face of the conventions of the time and was frowned on
by the pillars of society – and the servants. They were as
far removed from each other as could be in wealth and sta-
tus. Servants did not speak unless spoken to. But Servant
and Queen were equally strong-willed, stubborn and deter-
mined when it came to a goal worth fighting for! ‘Politically
correct’ barriers of etiquette were pushed, broached and
surmounted. A strong rapport was evident. The aim was
achieved.
To return to our ‘‘brave new partnership’’: there was
never any time wasted, right from the start: communica-
tion was direct, to the point and lively – indeed, one could
say, provocative and challenging; hence its productiveness.
For me, it was informative, stimulating and inspirational:
never oppressive or coercive. Sometimes with the gloves
really off! He exhibited immense patience with my igno-
rance of many subjects, gently and gradually leading me
to the literature. By inviting me to attend the Royal Mars-
den Hospital weekly Breast Unit Meetings, and copying
me in to various correspondences, he led me to identifica-
tion of leading players in the forefront of thought about
the moral obligation of patients to join randomised trials,6
but leaving me to take the initiative to respond or approach
them. Just such a letter was one to Dr. William Silverman
about his pending visit to Oxford to give the Archie
Cochrane ‘‘Effectiveness and Efficiency’’ Anniversary Lecture,
17th March 1994.73. ‘Matchmaking’ and meeting
Our first meeting took place at the Royal Marsden Hospital,
Fulham Road (and a Thai restaurant on the corner with
Sidney Street!), 9th April 1992. That corner is where he left
me, waving a hand up at the Royal Marsden Hospital fac¸ade,
saying ‘‘There are professors in there who would give their
eye teeth to have a paper published in the Viewpoint section
of The Lancet.’’ I replied that I hadn’t even seen a copy of
The Lancet at the time I wrote my piece. Early on he told me
that I should write – but I wondered then what I should write
about!
‘‘How did you meet?’’ ‘‘Where did you meet?’’ ‘‘Who
introduced you?’’ are questions that people like to ask, but
may be too reticent to voice, particularly if (as one can fre-
quently observe – no exception in this case!) partners seem
to be an unlikely match. The ‘matchmaker’ in this case was
Mr. Neil Orr, my breast surgeon in Colchester, Head of the
Breast Unit Team. This happened in November 1991, a couple
of months after I declined to participate in the UK DCIS Trial.
After being diagnosed, operated on and invited to join this trial
in September 1991, and had had time to research a little about
trials, about DCIS, about informed consent, and think about
these things, I had sent Neil Orr a summary of the practical,
moral and ethical reasons why I had not agreed to participate.
Neil Orr replied by return, telling me that he had taken the
liberty of photocopying what I had written and had sent it to
Professor Michael Baum and Professor Roger Blamey.
I now want you to try to imagine how I felt, as a very
ordinary lay member of the public, when I received a letter
the following month from Michael Baum, the day before
Christmas Eve. He stated that he ‘‘would enjoy continuing
this dialogue’’ with me by exchange of correspondence, and,
as Chairman of the Breast Cancer Trials Co-ordinating
Committee, he ‘‘would be very happy to meet me in Town to
discuss the matter in greater detail’’ having agreed with me
about the inadequacy of information for trial participants.8
It thus took the bold and decisive action of two breast sur-
geons, stepping outside their usual remit, having identified
potential for improvement to the process of seeking patients’
consent in research, to take personal initiatives to provide the
means for dialogue and action between two people from very
different backgrounds who were both concerned about this.
This action has to be set against the prevailing culture of the
time, when it was not normal to make this kind of approach
to a patient, when it might even be looked at askance by
some medical colleagues. It took a particular kind of physician
to identify the potential in this new alliance and pursue it
without hesitation or fear of criticism.
But I had kept something up my sleeve. When Michael
Baum wrote to me in December, he did not know that, when
I had written to Neil Orr in November, I had also sent a copy
of my piece to all the members of the DCIS Trial Steering
Group, and to several medical journals, not knowing, of
course, that this was not how things were done! The first ac-
ceptance of my piece came from The Lancet on 27th November
1991.9 They offered to publish it in the Viewpoint section of the
journal.10 Imogen Evans, the Senior Editor there, commented
‘‘Many of the arguments that you raise cast a completely
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see in this bold move, people taking unusual initiative –
a departure from the norm of that time; recognition of the
benefits of a new approach; a possible new contributory rela-
tionship between doctor and patient for the improvement of
the research process. Little did I think then that I would, one
day, co-author a book with Imogen Evans and Iain Chalmers
that added to this continued striving to educate the public
about the need for them to understand and be involved in
testing treatments, advocating for better research to achieve
better healthcare.114. The Lancet ‘Challenge of Breast Cancer’
conference, April 1994. CAG-CT
Michael Baum chaired the full morning session of The Lancet
‘Challenge of Breast Cancer’ conference in Brugge 22nd April
1994. Imogen Evans chaired the first session of the morning –
‘‘The patient’s role in research’’, in which I shared a platform
with Susan Love and Kay Dickersin. This was a prime oppor-
tunity for me to advocate to the assembled international
breast cancer specialists for sharing the responsibility to
test treatments.12 Subsequently, Michael was keen for me
to establish a constituency to take this forward. So, in Sep-
tember that year, 1994, we held the first meeting of our
jointly founded Consumers’ Advisory Group for Clinical Tri-
als (CAG-CT). The group immediately went to work on a draft
protocol for a randomised controlled trial; set about register-
ing ourselves as a charity; worked up our successful bid for
funding from the NHS R&D Cancer Programme to explore
the use of a Consumers’ Advisory Group to increase accrual
into trials; and drafted the first version of our leaflet outlining
our aims and objectives.5. Conclusion
Historical events are placed in context by dates.13 Detailing
and appreciation of strict chronological order are necessary
if proper and accurate interpretation of any event in its wider
context is to be undertaken. Leading dramatis personae need
patience and doggedness14: history cannot be hurried. Timing
of important events may be exquisitely precise; pace of events
will vary; long lapse of time is usually needed in order to be
able to draw reasonable inferences. Induction, deduction
and interpretation follow inexorably in sequence, rolling re-
lentlessly against the broad background of contiguous events.
At this celebration of Michael Baum’s lifework, we have
seen this to be so. He is a man of many skills, expertises and
talents. That he should have identified the potential in a con-
tinued dialogue and relationship with me, come what may,
through thick and thin, in pursuit of a common goal that stood
to benefit the lives of countless thousands of women, and also
improve the relationship between health professionals and
involved patients and public in testing treatments, whatever
their race, creed, colour or individual circumstances, is testi-
mony both to his wide vision and to his courage. We were
allies, even though ‘‘diametrically opposed’’ as he had said
in our first published debate.15,16 We had emerged ‘‘from thetwo distinct cultures of our society, with differing back-
grounds in the liberal arts and the biological sciences’’. He
relished dissent within the scientific process, for, as he said,
‘‘without dissent there can be no progress.’’ He pushed the
boundaries with his 1993 Lancet paper ‘‘new approach for
recruitment to randomised trials’’17: this was met with excite-
ment in my editorial commentary, but also with robust
challenge.18 It led on to organised, productive, brave new
partnerships in research, not just in breast cancer,19 but also
generally.
[Ductal Carcinoma In Situ (DCIS)]
‘‘It is much easier to write upon disease than upon a remedy. The
former is in the hands of nature, and a faithful observer, with an
eye of tolerable judgement, cannot fail to delineate a likeness. The
latter will ever be subject to the whims, the inaccuracies, and the
blunders of mankind’’.20 W. Witherington. 1785.Conflict of interest statement
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